Show simple item record

Assessment of Dyspnea Early in Acute Heart Failure: Patient Characteristics and Response Differences Between Likert and Visual Analog Scales

dc.contributor.authorPang, Peter S.en_US
dc.contributor.authorCollins, Sean P.en_US
dc.contributor.authorSauser, Korien_US
dc.contributor.authorAndrei, Adin‐cristianen_US
dc.contributor.authorStorrow, Alan B.en_US
dc.contributor.authorHollander, Judd E.en_US
dc.contributor.authorTavares, Miguelen_US
dc.contributor.authorSpinar, Jindrichen_US
dc.contributor.authorMacarie, Cezaren_US
dc.contributor.authorRaev, Dimitaren_US
dc.contributor.authorNowak, Richarden_US
dc.contributor.authorGheorghiade, Mihaien_US
dc.contributor.authorMebazaa, Alexandreen_US
dc.date.accessioned2014-08-06T16:49:54Z
dc.date.availableWITHHELD_11_MONTHSen_US
dc.date.available2014-08-06T16:49:54Z
dc.date.issued2014-06en_US
dc.identifier.citationPang, Peter S.; Collins, Sean P.; Sauser, Kori; Andrei, Adin‐cristian ; Storrow, Alan B.; Hollander, Judd E.; Tavares, Miguel; Spinar, Jindrich; Macarie, Cezar; Raev, Dimitar; Nowak, Richard; Gheorghiade, Mihai; Mebazaa, Alexandre (2014). "Assessment of Dyspnea Early in Acute Heart Failure: Patient Characteristics and Response Differences Between Likert and Visual Analog Scales." Academic Emergency Medicine (6): 659-666.en_US
dc.identifier.issn1069-6563en_US
dc.identifier.issn1553-2712en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108064
dc.description.abstractBackground Dyspnea is the most common symptom in acute heart failure ( AHF ), yet how to best measure it has not been well defined. Prior studies demonstrate differences in dyspnea improvement across various measurement scales, yet these studies typically enroll patients well after the emergency department (ED) phase of management. Objectives The aim of this study was to determine predictors of early dyspnea improvement for three different, commonly used dyspnea scales (i.e., five‐point absolute Likert scale, 10‐cm visual analog scale [ VAS ], or seven‐point relative Likert scale). Methods This was a post hoc analysis of URGENT Dyspnea, an observational study of 776 patients in 17 countries enrolled within 1 hour of first physician encounter. Inclusion criteria were broad to reflect real‐world clinical practice. Prior literature informed the a priori definition of clinically significant dyspnea improvement. Resampling‐based multivariable models were created to determine patient characteristics significantly associated with dyspnea improvement. Results Of the 524 AHF patients, approximately 40% of patients did not report substantial dyspnea improvement within the first 6 hours. Baseline characteristics were similar between those who did or did not improve, although there were differences in history of heart failure, coronary artery disease, and initial systolic blood pressure. For those who did improve, patient characteristics differed across all three scales, with the exception of baseline dyspnea severity for the VAS and five‐point Likert scale (c‐index ranged from 0.708 to 0.831 for each scale). Conclusions Predictors of early dyspnea improvement differ from scale to scale, with the exception of baseline dyspnea. Attempts to use one scale to capture the entirety of the dyspnea symptom may be insufficient. Resumen Antecedentes La disnea es el síntoma más frecuente en la insuficiencia cardiaca aguda ( ICA ), sin embargo no ha sido bien definida la mejor manera de medirla. Estudios previos demuestran diferencias en la mejoría de la disnea a través de varias escalas de medida, sin embargo estos estudios suelen reclutar pacientes bastante después de la fase de manejo en el SU . Objetivos El objetivo de este estudio fue determinar los predictores precoces de mejoría de la disnea para tres escalas de disnea diferentes frecuentemente utilizadas (escala Likert absoluta de 5 puntos, escala visual analógica [ EVA ] de 10 cm o escala Likert relativa de 7 puntos). Métodos Se trata de un análisis post hoc del estudio observacional Disnea URGENTE , que reclutó 776 pacientes dentro de la primera hora tras la primera valoración médica en 17 países. Los criterios de inclusión fueron amplios para reflejar la práctica clínica en el mundo real. La literatura previa documentó la definición a priori de la mejoría significativa de disnea. Se crearon modelos multivariables basados en el remuestreo para determinar las características de los pacientes significativamente asociadas con la mejoría de la disnea. Resultados De los 524 pacientes con ICA , aproximadamente un 40% de los pacientes no documentaron una mejoría sustancial de la disnea en las 6 primeras horas. Las características basales fueron similares entre los que mejoraron y los que no, aunque hubo diferencias en la historia de insuficiencia cardiaca, enfermedad coronaria y presión arterial sistólica inicial. Para aquéllos que mejoraron, las características del paciente difirieron en las tres escalas, con la excepción de la gravedad de la disnea basal para la EVA y en la escala Likert de 5 puntos (el índice‐c varió desde 0,708 hasta 0,831 para cada escala). Conclusiones Los predictores de la mejoría precoz de disnea difieren dependiendo de la escala, con la excepción de la disnea basal. Los intentos para utilizar una sola escala para categorizar la totalidad del síntoma disnea pueden ser insuficientes.en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleAssessment of Dyspnea Early in Acute Heart Failure: Patient Characteristics and Response Differences Between Likert and Visual Analog Scalesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108064/1/acem12390-sup-0001-DataSupplementS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108064/2/acem12390.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108064/3/acem12390-sup-0002-DataSupplementS2.pdf
dc.identifier.doi10.1111/acem.12390en_US
dc.identifier.sourceAcademic Emergency Medicineen_US
dc.identifier.citedreferenceMentz RJ, Hernandez AF, Stebbins A, et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30‐day outcomes: findings from ASCEND‐HF. Eur J Heart Fail 2013; 15: 456 – 64.en_US
dc.identifier.citedreferenceTeerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial. Lancet 2013; 381: 29 – 39.en_US
dc.identifier.citedreferencePang PS, Cleland JG, Teerlink JR, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008; 29: 816 – 24.en_US
dc.identifier.citedreferenceWest RL, Hernandez AF, O'Connor CM, Starling RC, Califf RM. A review of dyspnea in acute heart failure syndromes. Am Heart J 2010; 160: 209 – 14.en_US
dc.identifier.citedreferenceAllen LA, Metra M, Milo‐Cotter O, et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE‐AHF). J Card Fail 2008; 14: 777 – 84.en_US
dc.identifier.citedreferenceO'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32 – 43.en_US
dc.identifier.citedreferenceMebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT‐dyspnoea study. Eur Heart J 2010; 31: 832 – 41.en_US
dc.identifier.citedreferencePang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009; 30: 2233 – 40.en_US
dc.identifier.citedreferenceJohnson MJ, Oxberry SG, Cleland JG, Clark AL. Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review. Eur J Heart Fail 2010; 12: 137 – 47.en_US
dc.identifier.citedreferenceCollins SP, Peacock WF, Lindsell CJ, et al. S3 detection as a diagnostic and prognostic aid in emergency department patients with acute dyspnea. Ann Emerg Med 2009; 53: 748 – 57.en_US
dc.identifier.citedreferenceStevenson LW, Hellkamp AS, Leier CV, et al. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol 2008; 52: 1702 – 8.en_US
dc.identifier.citedreferenceGheorghiade M, Ruschitzka F. Beyond dyspnoea as an endpoint in acute heart failure trials. Eur Heart J 2011; 32: 1442 – 5.en_US
dc.identifier.citedreferenceGheorghiade M, Konstam MA, Burnett JC Jr, et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007; 297: 1332 – 43.en_US
dc.identifier.citedreferencePang PS, Gheorghiade M, Dihu J, et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials. Am Heart J 2011; 161: 1067 – 72.en_US
dc.identifier.citedreferenceBrieman L. Bagging predictors. Machine Learn 1996; 24: 123 – 40.en_US
dc.identifier.citedreferenceAnder DS, Aisiku IP, Ratcliff JJ, Todd KH, Gotsch K. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail 2004; 10: 188 – 91.en_US
dc.identifier.citedreferencePang PS, Tavares M, Collins SP, et al. Design and rationale of the URGENT Dyspnea study: an international, multicenter, prospective study. Am J Ther 2008; 15: 299 – 303.en_US
dc.identifier.citedreferenceYancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in‐hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 2006; 47: 76 – 84.en_US
dc.identifier.citedreferenceAbraham WT, Adams KF, Fonarow GC, et al. In‐hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57 – 64.en_US
dc.identifier.citedreferenceMetra M, Cleland JG, Weatherley BD, et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study. Eur J Heart Fail 2010; 12: 499 – 507.en_US
dc.identifier.citedreferenceMetra M, O'Connor CM, Davison BA, et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J 2011; 32: 1519 – 34.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.